Summary.-The effect of combinations of the conventional chemotherapeutic agent 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) and nitroimidazole radiation sensitizers was evaluated in female C3H mice. Tumour response to single-agent or combination therapy was assessed in a tumour growth-delay assay. In the KHT sarcoma the simultaneous addition of misonidazole (MISO) was found to increase significantly the tumour growth delay resulting from CCNU treatment. The observed enhancement ratios (ER) increased with MISO dose, and ranged from 1x3 to 1-9 for sensitizer doses of 0-25-1l0 mg/g. The combination of CCNU and 1-0 or 0-5mg/g MISO in the RIF-1 tumour or the MT-1 tumour produced ERs of -2-0 and -15 respectively.
MISO in the RIF-1 tumour or the MT-1 tumour produced ERs of -2-0 and -15 respectively.
In the KHT sarcoma a series of other nitroimidazole sensitizers, including Ro-05-9963, SR-2555, SR-2508 and metronidazole (METRO), were also evaluated at equimolar doses (5 mmol/kg) in combination with a 20mg/kg dose of CCNU. Unlike MISO, these compounds in general failed to enhance the CCNU cytotoxicity in this tumour model. However, SR-2508 did enhance the response of the RIF-1 tumour to large single doses of CCNU, though not as much as MISO.
Normal-tissue toxicity was determined using peripheral white blood cell (WBC) counts 3 days after treatment. CCNU doses of 10-50 mg/kg given either alone or in simultaneous combination with 0 5 or 1-0 mg/g MISO were studied. WBC toxicity increased with CCNU dose, but the addition of MISO at either dose did not significantly enhance this normal-tissue toxicity. THERE HAS RECENTLY been considerable interest in combining conventional chemotherapeutic agents and chemical radiation sensitizers in the treatment of animal tumour models. Such studies have been initiated because of evidence from both in vitro and in vivo tumour systems which has suggested that hypoxic tumour cells may be preferentially spared by some anti-tumour agents such as 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) Adriamycin, and nitrogen mustard (Hill & Stanley, 1975; Sutherland et al., 1978 Sutherland et al., , 1979 Hill, 1979) . Others have reported that the addition of a radiation sensitizer such as misonidazole (MISO) may enhance the tumour-cell cytotoxicity of some chemotherapeutic agents Rose et al., 1980; Clement et al., 1980; Tannock, 1980a,b; Mulcahy et al., 1981; Siemann, 1981; Law et al., 1981; Twentyman, 1981) . Depending on the agents, treatment conditions and tumour and normal tissue-response endpoints chosen, such combinations may potentially lead to a therapeutic advantage (Rose et al., 1980; Clement et al., 1980; Tannock, 1980a; Mulcahy et al., 1981; Siemann, 1981; Law et al., 1981) .
Our laboratory has previously reported on the effects of combination therapy with nitrosoureas and MISO or Ro-05-9963 (Mulcahy et al., 1981; Siemann, 1981) . This class of anti-tumour agent was chosen for combination with radiosensitizers because, at least in some murine tumours, hypoxic cells have been shown to be resistant to treatment with such agents (Hill & Stanley, 1975 (Thomson & Rauth, 1974) and passaged in vivo every 2 weeks. RIF-1 tumour cells were maintained and passaged alternately in vitro and in vivo, as in the protocol of Twentyman et al. (1980) . The first-generation mammary tumours (MT-1) were obtained by injecting cells from a frozen stock of a single-cell suspension prepared from a spontaneously arising mammary tumour Following the treatment the animals' tumours were measured daily by passing the tumourbearing legs through a plastic plate with increasing-diameter holes . The smallest hole the tumour-bearing leg would pass through was recorded, and converted to a tumour weight using a calibration curve obtained by excising and weighing the tumours of tumour-bearing legs of various sizes . The time for each tumour in each group to grow to 4 or 5 times the starting size was then recorded. In these studies, particularly in those groups receiving the sensitizer-chemotherapeutic agent combinations, a considerable range of tumour responses was found. Sometimes animals had to be killed for humane reasons before the tumours of others in the same treatment group reached the desired endpoint size. The use of mean tumour weights, therefore, was felt to be inappropriate, and the median time to reach 4-5 times the initial size was used for each group. Confidence intervals about the median were calculated using non-parametric statistics (Noether, 1971) .
Peripheral white blood cell (WBC) toxicity.-Peripheral WBC counts were determined from 10,ul samples taken from the tail veins of tumour-or non-tumour-bearing female C3H/HeJ mice. Before counting, the sample was diluted in 10 ml saline and the red blood cells lysed by adding RBC Studies with CCNU indicated a nadir in the number of white cells in the peripheral blood 3 days after treatment, as reported by others (Anderson et al., 1975) . In addition, the combination of CCNU + MISO produced a peripheral WBC minimum 2-4 days after injection. Consequently the effect of combining MISO at doses of 0-5 or 1-0 mg/g with CCNU over a range of CCNU doses was evaluated on Day 3.
RESULTS
The response of KHT sarcomas to CCNU alone or in combination with MISO is shown in Fig. 1 . The data in the left panel indicate that, at every dose of CCNU, the addition of a 1-0 mg/g dose of MISO significantly enhanced the tumour-growth delay. Reducing the dose of the sensitizer administered with this nitrosourea reduced the growth-delay enhancement (right panel). However, even at the lower doses of MISO (0.5 or 0-25 mg/g) there was a considerable improvement in tumour response to CCNU. The resultant enhancement ratios (ERs), defined as the dose of CCNU alone divided by the dose of CCNU + MISO to cause a given tumour effect, were determined for a CCNU dose of 30 mg/kg, and were found to be -1-9, 1-7 and 1-3 for MISO doses of 1-0, 0-5 and 0-25 mg/g respectively.
For comparison, the effect of combining CCNU and MISO also was assessed in a first-generation transplanted mammary tumour (MT-1) and the RIF-1 tumour (Fig. 2 ). Both these tumour models grow at a slower rate, and are considerably more resistant to treatment with CCNU than the KHT sarcoma. For example, (Fig. 1) .
In order to determine whether other commonly studied nitroimidazole sensitizers could mimic in the KHT sarcoma the enhanced tumour response to CCNU observed by the addition of MISO, the radiosensitizers metronidazole (METRO), Ro-05-9963, SR-2508 and SR-2555 in combination with CCNU also were studied in this tumour. MT-I . Fig. 3 illustrates results in the RIF-1 tumour for CCNU combined with SR-2508 at the same equimolar dose as MISO (5 mmol/kg). The data indicate that, unlike MISO, SR-2508 improves the tumour response to CCNU only at the largest doses of CCNU.
To assess normal-tissue toxicity, WBC counts were made on blood samples taken from the tails of C3H mice. In the initial investigation, WBC counts after treatment with single doses of 1 mg/g MISO, 20 mg/kg CCNU or their simultaneous combination were taken from non-tumour-bearing mice at various time intervals up to 28 days. The data showed that CCNU and CCNU + MISO treatments reduced WBC counts between Days 2 and 4, followed by recovery. The results on Day 3 are illustrated by the squares in Fig. 4 . In this experiment the combination of agents led to a WBC drop which was more severe and lasted longer than that with CCNU alone. Differential counts indicated that the leucocytes most affected by the single agent or the combination were the peripheral granulocytes, and that the nadir in these differential cell counts mirrored that seen in the total WBC counts. Little enhancement in kill of lymphocytes (compared to CCNU alone) was observed when MISO was added to the CCNU. These findings were similar to previous reports on nitrosourea effects on WBC numbers in mice (Anderson et al., 1975) . So Day 3, which showed a nadir for the singledose CCNU treatments as well as for the CCNU-MISO combination, was chosen for subsequent WBC toxicity evaluations. Fig. 4 shows total WBC counts 3 days after treatment with a range of CCNU doses given alone or simultaneously with either 1 0 or 0-5 mg/g MISO. The data indicate that, unlike the findings in the previously described preliminary study, when complete dose-response curves for CCNU and CCNU+MISO were obtained, to enhance tumour cytotoxicity in vivo (Clement et al., 1980; Rose et al., 1980; Tannock, 1980b; Mulcahy et al., 1981; Siemann, 1981; Law et al., 1981; Twentyman, 1981) . As has been reported previously (Siemann, 1981) , the combination of CCNU with MISO was particularly effective in the KHT sarcoma. The investigation of this combination has been extended in the present study, and tumour growth-delay dose-response curves for CCNU doses combined with a range of MISO doses were obtained (Fig.  1) . The results indicated that MISO could enhance the response of the KHT sarcoma to single doses of CCNU, even when the MISO dose was as low as 0-25 mg/g. This observation was qualitatively similar to the previous finding in the KHT sarcoma using a clonogenic-cell survival assay (Siemann, 1981) . However, in that investigation larger ERs were obtained than in the present report using tumourgrowth delay as the endpoint (Table II) . Larger ERs for BCNU+MISO have also been observed in our laboratories when tumour response was assessed by in vivo to in vitro clonogenic-cell survival than using in situ tumour growth delay (Mulcahy et al., submitted). Such apparent discrepancies between these two assays are not uncommon, and have previously been observed by many other authors studying the effects of a variety of treatments including radiation, chemotherapy, or combined-modality therapies on tumour response (Stephens & Peacock, 1977; Begg et al., 1980; McNally & de Ronde, 1980; Twentyman, 1980; Hill, 1980) . In order to determine whether the enhanced tumour responses to CCNU-MISO combinations were specific to the KHT sarcoma, the effect of such treatments also were evaluated in the RIF-1 tumour as well as in a first-generation transplanted mammary tumour. Even though CCNU alone was found to be less effective in these two systems than in the KHT tumour, the relative ERs on the addition of MISO were similar ( Fig. 2 and Table II ).
Since other nitroimidazole sensitizers have been used or considered for clinical application, their ability to enhance to toxicity of CCNU also was tested. For comparison, these sensitizers were combined with CCNU at the same mmol/kg dose as MISO. Complete dose-response curves were not determined, yet even the single-dose combinations (Table I) indicated that, when administered simultaneously with CCNU, MISO was clearly superior to METRO, Ro-05-9963, SR-2508 and SR-2555 in enhancing the efficacy of CCNU in the KHT sarcoma. However, the data in Fig. 3 showed that in the RIF-1 tumour, SR-2508 also enhanced the effect of CCNU, though only for large CCNU doses. These results for different nitroimidazole sensitizers clearly require further investigation.
As we have suggested previously (Mulcahy et al., 1981; Siemann, 1981) , the enhancement of tumour response to alkylating chemotherapeutic agents by nitroimidazole sensitizers could be due to: (1) cytotoxicity of sensitizer in cells spared by the anti-tumour agents, (2) altered drug pharmacokinetics, (3) sensitization of the tumour to the chemotherapeutic agent by the sensitizer, and (4) inhibition of the repair of the chemotherapeutic agent's potentially lethal damage (PLD) by the sensitizer.
The first possibility appears highly unlikely, since MISO causes no tumourgrowth delay and minimal cell kill in the KHT sarcoma until doses in excess of 1 mg/g are administered (Mulcahy et al., 1981a, submitted; Siemann, 1981 ). Yet even doses as low as 0-25 and 0-5 mg/g of this sensitizer can enhance considerably the tumour response to CCNU (Table II) .
With respect to the altered-pharmacokinetics hypothesis, results to date are conflicting. Findings in our laboratory with a related nitrosourea (BCNU) and CY have indicated that the MISO pharmacokinetics are not altered when these two agents are combined with this sensitizer. Also, the addition of MISO has been shown not to alter the pharmacokinetics 278 of BCNU in mice (Tannock, 1980b) or in patients (Urtasun et al., 1982) . Similar studies on the in vivo pharmacokinetics of CCNU in the presence or absence of MISO do not exist. However, since CCNU, unlike BCNU, undergoes ring hydroxylation by liver microsomal enzymes (May et at., 1974; Hilton & Walker, 1975; Wheeler et al., 1977) the possibility arises that the enhanced tumour response on the addition of MISO to CCNU treatment could be the result of altered CCNU metabolism in the presence of the sensitizer. The observations in the KHT sarcoma could be interpreted as supporting this view, since MISO, which undergoes oxidative demethylation, probably by liver microsomal mixed-function oxidases, enhances the cytotoxicity of CCNU, whereas Ro-05-9963 and SR-2508 are not metabolized in this manner (White et al., 1980) and are relatively ineffective (Table I ). However, other have shown that hydroxylation of the cyclohexane ring of CCNU leads to metabolites which have slightly better therapeutic indices (Wheeler et al., 1977) or tumour efficacies similar (Johnston et al., 1975) to that of the parental CCNU. In addition, while an enhanced rate of CCNU metabolism has been reported in phenobarbital-pretreated animals (Hilton & Walker, 1975) such treatments did not alter significantly CCNU anti-tumour activity (Levin et al., 1979) . However, preliminary data in this laboratory (Siemann, unpublished) have indicated that phenobarbital pretreatment can reduce, by about the same factor, both the response of the KHT sarcoma and the degree of normal-tissue toxicity due to CCNU administration. Also, , have shown that SKF-525A, an inhibitor of drug-metabolizing enzymes, can enhance the tumoricidal effects of CCNU. Finally, in contrast to the results obtained with MISO, the 5-nitroimidazole METRO, which undergoes oxidative metabolism (Ings et at., 1966) , did not enhance the response of the KHT sarcoma to CCNU. In addition, SR-2508 effectively enhanced the efficacy of CCNU in the RIF-1 tumour (Fig. 3) , though only at the largest doses of CCNU. Thus, whilst altered chemotherapeutic-agent metabolism may not be the primary mechanism for the enhanced tumour response to CCNU-sensitizer combinations, further evaluation of the interactions between anti-tumour agents and sensitizers is clearly required.
Sensitization of the tumour cells to the chemotherapeutic agent, perhaps analogous to sensitization to radiation of hypoxic cells, is another possible mechanism of the sensitizer effect. In support of this view, Tannock (1980b) has shown that, whilst the serum of mice treated with BCNU or BCNU+MISO was equally toxic to cells exposed in vitro under aerobic conditions, the combination was much more toxic to anaerobic cells. The present results yield little information about this possible mechanism. However, other studies (Siemann & Mulcahy, 1982) have indicated that, depending on the chemotherapeutic agent used, the enhanced tumour response to MISO-chemotherapeutic-agent combinations may result both from a potentiation of the chemotherapeutic agent's cytotoxic effects and/or an inhibition of the clonogenic-cell recovery, measured as a function of time after treatment. When CCNU and MISO were combined, the major effect of the sensitizer appeared to be on the recovery in clonogenic-cell survival, such that 24 h after treatment tumour-cell survival in mice receiving the combination treatment was about 2% of that in mice given only CCNU. Similar cell-survival responses have also been observed by Law et al. (1981) for combinations of CY and MISO in the RIF-1 tumour. Thus, although the present investigation does not allow us to determine the mechanism of the enhanced tumour response with certainty, other data suggest that inhibition of recovery of clonogenic-cell survival plays a major role in the large ERs observed with the CCNU-MISO combination in the KHT sarcoma.
It is of interest to note that, unlike MISO, the other sensitizers evaluated in combination with 20 mg/kg CCNU were ineffective in the KHT sarcoma (Table I) . At an equimolar dose, SR-2508 did enhance the response of the RIF-1 tumour to CCNU, though not to the same extent as MISO, and not at all at lower doses of CCNU (Fig. 3) . Enhancement of CY damage by SR-2508 has also been found in the RIF-1 tumour (Law et al., 1981) and KHT sarcoma (Siemann & Sutherland, 1982) . These findings imply that there may be some degree of both tumour and chemotherapeutic-agent specificity when different radiosensitizers are used to modify the tumoricidal action of anti-tumour agents.
Experiments in our laboratories with nitrosoureas of different alkylating and carbamoylating activities, have also shown that the particular nitrosourea chosen may be a key factor in the level of enhancement of tumour-cell kill on the addition of MISO. Of the nitrosoureas studied, CCNU, which was the most carbamoylating agent tested, gave the largest enhancement ratio when combined with MISO. In contrast, the addition of MISO to chlorozotocin, a nitrosourea with relatively little carbamoylating activity, had no effect (Mulcahy et al., submitted) . Further evaluations of various nitrosoureas and radiation sensitizers in vitro are in progress.
Finally the question of enhanced therapeutic gain needs to be considered. Using gut toxicity and depression of WBC numbers as endpoints, investigations in this laboratory have indicated a greater effect in the tumour than the normal tissues when CCNU and MISO are combined. These findings imply that an improved therapeutic result may be achieved through such a combination. Nevertheless, the extension of combinations of chemotherapeutic agents and radiation sensitizers to the clinic should be done cautiously.
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